Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Amyris (AMRS) upgraded at Morgan Stanley from Equal-weight to Overweight. $32 price target. Company continues to execute on its growth strategy.
Cameron International (CAM) upgraded at Credit Suisse from Neutral to Outperform. $73 price target. Very strong orders.EMC (EMC - Get Report) upgraded at Oppenheimer from Perform to Outperform. $32 price target. Stock is attractive, following a recent pullback. East West Bancorp (EWBC - Get Report) upgraded at FBR from Market Perform to Outperform. $23 price target. Stock is attractively valued, following a recent pullback. Exelon (EXC - Get Report) upgraded at UBS from Neutral to Buy. $50 price target. Cost synergy story and leverage to power recovery. Jazz Pharmaceuticals (JAZZ - Get Report) upgraded at Jefferies to Buy. $52 price target. Estimates also upped, given recent Xyrem growth. Oceaneering International (OII) downgraded at Credit Suisse from Outperform to Neutral. $48 price target. Central theses played out. Oil States (OIS) upgraded at Credit Suisse from Neutral to Outperform. $110 price target. Stock should continue to deliver higher earnings. Rockwell Automation (ROK) upgraded at Baird from Neutral to Outperform. $92 price target. Company can continue to deliver solid growth over the coming years. RadioShack (RSH) upgraded at Goldman from Neutral to Buy. Company was also added to the Conviction Buy list. $18 price target. Company is improving its position in the wireless market. Vanguard Health (VHS - Get Report) rated new Overweight at JP Morgan. $22 price target. Company has attractive exposure to urban markets. Vodafone (VOD) upgraded at UBS from Neutral to Buy. $31.05 price target. VZW dividend larger than expected. Vertex Pharmaceuticals (VRTX - Get Report) upgraded at Citigroup from Hold to Buy. $60 price target. Incivek should not disappoint.
End of report.